Share on StockTwits

Hikma Pharmaceuticals Plc (LON:HIK) has received an average recommendation of “Hold” from the nine brokerages that are presently covering the stock, Analyst Ratings.Net reports. Five analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is GBX 1,698.57 ($28.58).

A number of analysts have recently weighed in on HIK shares. Analysts at Barclays reiterated an “overweight” rating on shares of Hikma Pharmaceuticals Plc in a research note on Friday, August 1st. Separately, analysts at Jefferies Group raised their price target on shares of Hikma Pharmaceuticals Plc from GBX 1,600 ($26.92) to GBX 1,610 ($27.09) in a research note on Friday, August 1st. They now have a “hold” rating on the stock. Finally, analysts at Goldman Sachs upgraded shares of Hikma Pharmaceuticals Plc to a “buy” rating in a research note on Friday, July 18th. They now have a GBX 2,250 ($37.86) price target on the stock, up previously from GBX 1,800 ($30.29).

Shares of Hikma Pharmaceuticals Plc (LON:HIK) opened at 1686.00 on Tuesday. Hikma Pharmaceuticals Plc has a one year low of GBX 1004.00 and a one year high of GBX 1835.00. The stock has a 50-day moving average of GBX 1733. and a 200-day moving average of GBX 1568.. The company’s market cap is £3.334 billion.

Hikma Pharmaceuticals PLC is engaged in the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.